Kirilova, E.
Johansson, H.
Kirilov, N.
Vladeva, S.
Petranova, T.
Kolarov, Z.
Liu, E.
Lorentzon, M.
Vandenput, L.
Harvey, N. C.
McCloskey, E.
Kanis, John A.
Funding for this research was provided by:
University of Sheffield
Article History
Received: 11 November 2019
Accepted: 29 December 2019
First Online: 27 February 2020
Compliance with ethical standards
:
: E Kirilova, H Johansson, N Kirilov, S Vladeva, T Petranova, E Liu, L Vanderput and Z Kolarov declare that they have no competing interests. M Lorentzon has received lecture or consulting fees from Amgen, Lilly, UCB Pharma, Radius Health, Renapharma, Meda, GE-Lunar, Consilient Health and Tromp Medical. NC Harvey reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma outside the submitted work. EV McCloskey reports personal fees, consultancy, lecture fees, research support and/or honoraria from Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, UCB, Warner Chilcott outside the submitted work. He also reports research support from Versus Arthritis, I3 Innovus, MRC and IOF outside the submitted work. JA Kanis reports grant support from Amgen, Lilly and Radius Health.